Center for Matrix Biology and Medicine, Graduate School of Medicine, Tokai University, Isehara, Japan.
Department of Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan.
Stem Cells. 2019 Jan;37(1):89-101. doi: 10.1002/stem.2916. Epub 2018 Oct 31.
Granulocyte colony stimulating factor (G-CSF) has been reported to ameliorate impaired liver function in patients with advanced liver diseases through mobilization and proliferation of hepatic progenitor cells (HPCs). However, the underlying mechanisms remain unknown. We previously showed that G-CSF treatment increased the number of bone marrow (BM)-derived cells migrating to the fibrotic liver following repeated carbon tetrachloride (CCl ) injections into mice. In this study, we identified opioid growth factor receptor-like 1 (OGFRL1) as a novel BM cell-derived accelerator of fibrotic liver regeneration in response to G-CSF treatment. Endogenous Ogfrl1 was highly expressed in the hematopoietic organs such as the BM and spleen, whereas the liver contained a relatively small amount of Ogfrl1 mRNA. Among the peripheral blood cells, monocytes were the major sources of OGFRL1. Endogenous Ogfrl1 expression in both the peripheral blood monocytes and the liver was decreased following repeated CCl injections. An intrasplenic injection of cells overexpressing OGFRL1 into CCl -treated fibrotic mice increased the number of HPC and stimulated proliferation of hepatic parenchymal cells after partial resection of the fibrotic liver. Furthermore, overexpression of OGFRL1 in cultured HPC accelerated their differentiation as estimated by increased expression of liver-specific genes such as hepatocyte nuclear factor 4α, cytochrome P450, and fatty acid binding protein 1, although it did not affect the colony forming ability of HPC. These results indicate a critical role of OGFRL1 in the mobilization and differentiation of HPC in the fibrotic liver, and administration of OGFRL1-expressing cells may serve as a potential regenerative therapy for advanced liver fibrosis. Stem Cells 2019;37:89-101.
粒细胞集落刺激因子 (G-CSF) 已被报道通过动员和增殖肝祖细胞 (HPC) 来改善晚期肝病患者的肝功能障碍。然而,其潜在机制尚不清楚。我们之前的研究表明,G-CSF 治疗可增加骨髓 (BM) 来源的细胞数量,这些细胞在反复向小鼠注射四氯化碳 (CCl ) 后迁移到纤维化的肝脏。在这项研究中,我们确定阿片样生长因子受体样 1 (OGFRL1) 是一种新的 BM 细胞衍生的物质,可促进 G-CSF 治疗后纤维化肝脏的再生。内源性 Ogfrl1 在造血器官(如 BM 和脾脏)中高度表达,而肝脏中含有相对较少的 Ogfrl1 mRNA。在外周血细胞中,单核细胞是 OGFRL1 的主要来源。反复 CCl 注射后,外周血单核细胞和肝脏中的内源性 Ogfrl1 表达减少。向 CCl 处理的纤维化小鼠脾内注射过表达 OGFRL1 的细胞,可增加 HPC 的数量,并刺激纤维化肝脏部分切除后的肝实质细胞增殖。此外,在培养的 HPC 中过表达 OGFRL1 可加速其分化,如通过增加肝核因子 4α、细胞色素 P450 和脂肪酸结合蛋白 1 等肝脏特异性基因的表达来评估,但它不影响 HPC 的集落形成能力。这些结果表明 OGFRL1 在纤维化肝脏中 HPC 的动员和分化中起关键作用,并且过表达 OGFRL1 的细胞的给药可能作为一种潜在的再生疗法用于晚期肝纤维化。Stem Cells 2019;37:89-101.